9 Newly Approved Novel Drugs
It's been a busy year for the FDA.
2. Parsabiv (etelcalcetide), Amgen
Indication: A calcimimetic approved to manage secondary hyperparathyroidism in adults with chronic kidney disease who are on hemodialysis.
Dosage: Recommended starting dose is 5 mg by IV bolus injection three times per week at the end of hemodialysis treatment.
Contraindications: Known hypersensitivity to etelcalcetide or any of its excipients.